Monopar (MNPR) Stock Target Raised to $125 Following NDA Filing

H.C. Wainwright has increased the price target for Monopar Therapeutics (MNPR) to $125 following the company's filing of a New Drug Application (NDA). This adjustment reflects confidence in Monopar's pipeline and upcoming events related to their drug developments. The new target may influence investor sentiment and trading volumes as the market reacts to the positive developments. For ordinary investors, understanding these changes helps gauge potential stock performance and investment opportunities in Monopar.